PMP22 and Charcot-Marie-Tooth disease type 1A: Since our treatment is not intended to be applied to individuals with normal levels of PMP22 expression, the partial phenotype observed in WT mice based on the dual human-murine targeting capacity of miR871 does not raise safety concerns regarding the potential treatment of patients with CMT1A.